Qilu Pharmaceutical Group ranked ninth among China's top 100 pharmaceutical companies according to a list released by the China National Pharmaceutical Industry Information Center at the 2021 China Pharmaceutical Industry Information Conference, which was held in Jinan on Aug 1. It was also the sixth time that Qilu Pharmaceutical made the top 10 on the list.

With more than 40 years of development, Qilu Pharmaceutical has become one of the leading pharmaceutical enterprises in China. In 2020, its sales revenue reached 27.5 billion yuan ($4.26 billion), with a year-on-year growth of more than 20 percent.

Qilu Pharmaceutical has 10 production bases in China, with a strong industrial foundation. It has formed a whole industrial chain system integrating the R&D of products, production, and sales.

Adhering to a patient-centered and clinical value-oriented approach, the company has developed and marketed more than 300 drugs. A total of 47 products are catered to the domestic market, creating a distinctive product line covering anti-cancer, anti-infection, cardiovascular, mental, neurological, ophthalmology, liver disease, and AIDS drugs.

The company's products are exported to more than 80 countries and regions. The company is also the only one in China to export pharmaceutical products to Europe, the United States, Britain, Japan, and Australia. Its cephalosporin preparation series ranked first in terms of Australian market share.

Qilu Pharmaceutical is focusing on innovation. It has built various advanced R&D platforms and technology platforms for drug development.

The company is increasing its investment in research and development. Its R&D investment accounted for 11.8 percent of sales revenue in 2021.